Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
- Published In:
- International journal of pharmaceutics, 551(1-2), 14-22 (2018)
- Authors:
- Xiang, Yucheng, Shan, Wei, Huang, Yuan(2)
- Database ID:
- RPEP-03992
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03992APA
Xiang, Yucheng; Shan, Wei; Huang, Yuan. (2018). Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.. International journal of pharmaceutics, 551(1-2), 14-22. https://doi.org/10.1016/j.ijpharm.2018.09.011
MLA
Xiang, Yucheng, et al. "Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.." International journal of pharmaceutics, 2018. https://doi.org/10.1016/j.ijpharm.2018.09.011
RethinkPeptides
RethinkPeptides Research Database. "Improved anticancer efficacy of doxorubicin mediated by huma..." RPEP-03992. Retrieved from https://rethinkpeptides.com/research/xiang-2018-improved-anticancer-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.